Cancer Prevention Program
Colony-stimulating factor (CSF) is prescribed to patients undergoing a chemotherapy regimen that carries a high risk of febrile neutropenia (FN). FN is a serious, life-threatening complication, which can result in hospitalization and death, and disrupt treatment, compromising the likelihood of remission or cure. Although practice guidelines for prescribing preventive CSF based on chemotherapy risk levels for FN are widely available, studies show that CSF is both over- and under-used, exposing patients to unnecessary risk and cost. To address this, HICOR has partnered with Columbia University Medical Center, University of Washington, and SWOG to implement the TrACER Study with funding from the Patient Centered Outcomes Research Institute (PCORI) and the National Cancer Institute’s (NCI) Community Oncology Research Program.
TrACER is the first pragmatic trial in an NCI cancer cooperative group setting, the first cluster-randomized trial in SWOG, and in the first wave of large pragmatic clinical studies funded by PCORI. The pioneering study investigates whether a guideline-informed standing, order for administering preventive CSF improves guideline adherence and reduces the incidence of FN. The study will also assess the impact of preventive CSF in patients receiving intermediate risk chemotherapy. Forty-five clinics across the country are participating in the study.